Expedited Investigational New Drug Pilot Program; Request for Information; Correction

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2026-N-4699] AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 24, 2026. That notice opened a public docket to solicit input and comments on a proposal to establish a pilot program, the Expedited Investigational New Drug pilot program, to shorten the time it takes from drug identification to first-in-human study, while protecting clinical trial participants. FDA is correcting the email address of the document. FOR FURTHER INFORMATION CONTACT: Benjamin Cook, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 2, Rm. 2114, Silver Spring, MD 20993-0002, 240-338-4685, ExpeditedINDPilot@fda.hhs.gov . SUPPLEMENTARY INFORMATION: In the Federal Register of Wednesday, June 24, 2026 ( 91 FR 37996 ), in FR Doc. 2026-12621 , the following correction is made: On page 37997, in the third column, in the FOR FURTHER INFORMATION CONTACT section, the email is corrected to ExpeditedINDPilot@fda.hhs.gov . Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs. [ FR Doc. 2026-13592 Filed 7-2-26; 8:45 am] BILLING CODE 4164-01-P